



Renewals of terms of office for members of MaaT Pharma's Board of Directors

Based on the proposal by the Nomination and Corporate Governance Committee, the Board of Directors of MaaT Pharma proposes to submit the renewals of all current directors to the vote of the shareholders at the Company's next Annual General Meeting to be held on June 19, 2023. The Company invites its shareholders to refer to the 2022 Universal Registration Document for more information on the directors whose term of office is up for renewal, which is available on the website www.maatpharma.com.

Jean-Marie Lefèvre, Chairman of the Board

Jean-Marie Lefèvre, 63, has been Chairman of the Board of Directors of MaaT Pharma since 2016 and is a member of the Audit Committee.

A graduate of the Ecole Centrale de Paris and INSEAD, Jean-Marie Lefèvre has held senior management positions in large companies such as LVMH and Bongrain before joining Biocodex where he was Chairman and CEO until the end of 2020 and of which he is currently Chairman. During his tenure as CEO at Biocodex, he initiated the creation of numerous subsidiaries, and greatly diversified the product portfolio of the Biocodex Group. At the same time, he wanted his Group to invest in and support the development of healthcare start-ups, including MaaT Pharma.



Hervé Affagard, Director

Hervé Affagard, 49, is co-founder and CEO of MaaT Pharma.

Hervé Affagard holds a DESS from the University of Rouen and an Executive MBA from EM Lyon. Hervé Affagard has previously worked as an entrepreneur-in-residence for investment fund companies in the healthcare sector and has held several positions in the field of medical biology and in vitro diagnostics. Hervé Affagard brings to MaaT Pharma his expertise in the field of Health, and his ability to translate medical concepts into a concrete plan.



Claude Bertrand, Independent Director

Claude Bertrand, 60, is Executive Vice President R&D and Chief Scientific Officer at Servier Group.

Claude Bertrand joined the Board of Directors of MaaT Pharma in 2020 as an independent member and is also a member of the Nominating, Compensation Committee.

Claude Bertrand held a PhD in pharmacology and in Pharmacy from the University of Strasbourg. He brings decades of high-level experience in pharmaceutical development, having held various positions within major pharmaceutical groups such as Ipsen, AstraZeneca, Novartis, Roche and Pfizer.



Isabelle de Crémoux, Director

Isabelle de Crémoux, 53, is CEO and Managing Partner of Seventure Partners and leads the Life Sciences team. She is also a non-executive director at MaaT Pharma since 2014.

A graduate of Ecole Centrale Paris, Isabelle de Crémoux brings over 25 years of international experience in Business Development and Finance in the pharmaceutical industry, having held positions in major groups such as Pfizer and Laboratoires Fournier/Abbott. Isabelle de Crémoux has a particular interest in microbiome and regularly speaks at international conferences to share her vision in this field and her expertise as an investor in Life Sciences in general. In partnership with Danone and Novartis, Isabelle de Crémoux created the Health for Life Capital™ fund, which aims to invest primarily in microbiome companies and is one of the shareholders of MaaT Pharma.

Seventure Partners is represented by Isabelle de Crémoux.

**Dorothee Burkel, Independent Director**

Dorothee Burkel, 59, joined the Board of Directors of MaaT Pharma in 2021 as an independent director. She is also the President of the Nominating, Compensation Committee as well as the President of the CSR Committee.

Dorothee Burkel holds a master's degree from the Institut d'Etudes Politiques de Paris and was Chief Corporate and People Operations Officer and member of the Executive Committee of PartnerRe until October 2022. She brings decades of high-level experience in human resources and communication, having been involved in the transformation of companies internationally in the new technology and financial sector. She has also held the positions of HR Director EMEA at Google and HR Director France at AOL.

**Jean Volatier, Independent Director**

Jean Volatier, 58, is Chief Financial Officer and Deputy CEO of Inventiva and independent director of MaaT Pharma since 2021. Jean Volatier is also the President of the Audit Committee and a member of the CSR Committee. He holds a master's degree in management sciences from the University of Paris IX Dauphine (PSL), a DSCG and an Executive Specialized Master's degree in Global Management of CSR from Mines Paris Tech (PSL).

Jean Volatier brings several decades of experience in financial, CSR and investor relations. Jean began his career at Pricewaterhouse Coopers in Paris and Philadelphia, USA. He then moved on to various positions in the Finance Department, first at Laboratoires URGO Soins & Santé and then internationally at Laboratoires Fournier. He then held various administrative and financial director positions at Soufflet and NAOS groups.

